On Friday, the Minnesota Department of Agriculture issued an alert for Gerber Soothe 'N' Chew Teething Sticks. The alert ...

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, ...

Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial’s primary endpoint, progression-free survival (PFS) by independent radiologic review committee (IRRC), ...

Ivonescimab is the first therapy to achieve statistically significant positive results in a Phase III trial compared with ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Citi says the China National Medical Products Administration has just approved ivonescimab in first-line metastatic non-small cell lung cancer ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Investing.com -- Summit Therapeutics Inc. (NASDAQ: SMMT) stock plummeted 37% after the company announced an interim analysis requested by Chinese health authorities showed a positive trend for its ...

Akeso (AKESF) announced that its “globally first-in-class PD-1/VEGF bispecific antibody,” ivonescimab, has received approval from the National ...

The use of antibiotics in early childhood is associated with an increased risk for pediatric conditions such as asthma, food ...

For patients with bronchiectasis, brensocatib leads to a lower annualized rate of pulmonary exacerbations, according to a ...

Two of the 5 identified most common food additive mixtures were associated with higher type 2 diabetes incidence.